NYSE · MRK
Merck & Co.., Inc.
$130.76 -$0.31 (-0.24%) 1D After hours
Session Pulse
Overnight session
1
mentions on Fri
· 1 bullish
/ 0 bearish tags
No new SEC filings since Mon close
its sector ranked
5/11
this week
Full pulse →
Key Metrics
$323.72B
Market cap
36.23×
P/E · TTM
$65.77B
Revenue · TTM
$8.94B
Net income
EPS · TTM
$3.53
Dividend yield
2.5%
Free cash flow
$14.12B
Beta · 1Y
0.13
EBITDA · TTM
$14.75B
Gross margin
—
Snapshot
Market cap$323.72B
Enterprise value$366.03B
Shares outstanding2.5B
52-wk range$76.66 – $132.53
Avg volume · 20D10.9M
Net cash
−$42.31B
Book value / share$18.13
IndustryPharmaceutical Preparations
ExchangeNYSE
About Merck & Co.., Inc.
IPO dateApr 20, 1949
Employees75000
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E36.23
P/S4.92
P/FCF22.93
EV/EBITDA24.81
EV/Sales5.57
Graham №$37.94
Profitability
Gross
—
Operating
17.7%
Net
13.6%
FCF
21.5%
ROE / ROIC
19.4% · 10.0%
Financial Health
Current ratio1.30
Quick ratio1.06
Debt / equity1.07
Debt / EBITDA
3.33
Net cash
−$42.31B
Working capital$8.07B
Cash Flow · TTM
Operating CF
$17.89B
Capex
−$3.78B
Free cash flow
$14.12B
Buybacks
$4.79B
Dividends paid
$8.23B
Shareholder yield
4.0%
Piotroski F-Score
3 / 9
Weak fundamentals · 3 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
$37.94 vs $130.76
Trades 3.4× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings